TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07039916: Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

Sponsor: Immunovant Sciences GmbH · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 231 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,630,088

Rescue Site Savings

+$2,404,344

Unlock Full NCT07039916 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07039916 Rescue Dossier →